ESTRO 2024 - Abstract Book

S1238

Clinical - Head & neck

ESTRO 2024

status, and chemotherapy use, TPT>100 days was not associated with OS (adjusted HR: 1.03, 95% CI 0.83-1.28, p=0.77). Subgroup multivariable analysis were conducted among higher risk patients including those with positive margins or advanced pathological stage defined as pathological T3-T4 or pathological N1-N3 disease. TPT>100 days was not associated with OS for either group (adjusted HR for positive margins: 1.09, 95% CI 0.84-1.42, p=0.50 and adjusted HR for advanced pathological stage: 1.06, 95% CI: 0.83-1.36, p=0.62).

Conclusion:

A prolonged TPT >100 days was not associated with inferior OS in ACC. Clinicians can feel assured that prolonging treatment package time when necessary for additional surgery, recovery from surgery or for obtaining additional imaging to better guide RT planning will not have an adverse effect on survival outcomes, even among patients with advanced pathological stage or positive margins. These findings should be confirmed in larger multi-institutional studies.

Keywords: adenoid cystic, treatment package time, survival

1006

Proffered Paper

Prediction of cisplatin tolerance during chemoradiation in older HNSCC patients: A multicenter study

Alexander Rühle 1,2 , Sebastian Marschner 3 , Carmen Kut 4 , Marlen Haderlein 5 , Alexander Fabian 6 , Carolin Senger 7 , Johannes Kraft 8 , Jens von der Grün 9,10 , Eric Chen 11 , Justus Domschikowski 6 , Alev Altay-Langguth 9,3 , Goda Kalinauskaite 7 , Victor Lewitzki 8 , Konstantinos Ferentinos 12 , Constantinos Zamboglou 12,1 , Sören Schnellhardt 5,13 , Matthias Guckenberger 10 , Claus Belka 3 , Arnulf Mayer 14 , Heinz Schmidberger 14 , Anca-Ligia Grosu 1 , Panagiotis Balermpas 10 , Carmen Stromberger 7 , Harry Quon 4 , Nils H Nicolay 1,2 1 University of Freiburg – Medical Center, Department of Radiation Oncology, Freiburg, Germany. 2 University of Leipzig Medical Center, Department of Radiation Oncology, Leipzig, Germany. 3 University Hospital, LMU Munich, Department of Radiation Oncology, Munich, Germany. 4 Johns Hopkins University, Department of Radiation Oncology, Baltimore, USA. 5 Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Radiation Oncology, Erlangen, Germany. 6 University Hospital Schleswig-Holstein, Campus Kiel, Department of Radiation Oncology, Kiel, Germany. 7 Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Radiation Oncology, Berlin, Germany. 8 University Hospital Würzburg, Department of Radiation Oncology, Würzburg, Germany. 9 Goethe University Frankfurt, Department of Radiotherapy and Oncology, Frankfurt, Germany. 10 University Hospital Zurich, University of Zurich, Department of Radiation Oncology, Zurich, Switzerland. 11 University Hospitals Seidman Cancer Center, Department of Radiation Oncology, Cleveland, USA. 12 German Oncology Center, European University of Cyprus, Department of Radiation Oncology, Limassol, Cyprus. 13 Saarland University Medical Center, Department of Radiotherapy and Radiation Oncology, Homburg, Germany. 14 University Medical Center Mainz, Department of Radiation Oncology and Radiation Therapy, Mainz, Germany